Welcome to our dedicated page for Heartbeam SEC filings (Ticker: BEAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on portable ECG-based cardiac monitoring. These regulatory documents help investors and analysts understand how the company describes its business, technology, risks, and capital structure.
HeartBeam’s filings under the Securities Exchange Act of 1934 include, among others, current reports on Form 8-K. For example, an 8-K dated November 20, 2025 reports receipt of a Not Substantially Equivalent (NSE) letter from the U.S. Food and Drug Administration (FDA) related to the company’s 510(k) application for its 12-lead ECG synthesis software, and notes that the company stands behind its clinical data and intends to work with the FDA toward a resolution. The same filing confirms that HeartBeam’s common stock and warrants trade on NASDAQ under the symbols BEAT and BEATW and identifies the company as an emerging growth company.
On Stock Titan, HeartBeam’s SEC filings are updated in near real time as they are posted to the EDGAR system. Users can review annual and quarterly reports, when available, for detailed discussions of operating expenses, research and development activities, and liquidity, as well as risk factors related to regulatory approvals and commercialization of its cardiac monitoring technologies.
AI-powered tools on this page help explain complex filings by summarizing key points, highlighting material events, and pointing out items that may be important to investors, such as regulatory updates, capital raises, or changes in stockholders’ equity. Users can also quickly locate information about cleared indications for use of the HeartBeam System, descriptions of the 3D ECG and 12-lead synthesis technology, and references to the company’s patent portfolio as disclosed in its reports.
For those tracking insider and executive activity, Form 4 and related ownership filings, when available, can be used to monitor transactions in HeartBeam’s securities. Together, these documents offer a structured view of HeartBeam’s regulatory history, financial reporting, and significant corporate events.
HeartBeam, Inc. director Marga Ortigas-Wedekind received a grant of stock options representing the right to buy 44,827 shares of common stock at an exercise price of $1.43 per share. This is a compensation-related award, not an open-market share purchase or sale.
According to the grant terms, one half of the options, covering 22,413.5 underlying shares, will vest on March 31, 2026, and the remaining half will vest on June 30, 2026. The options were issued under HeartBeam’s 2022 Equity Incentive Plan and expire on January 1, 2036, giving the director a long-term incentive tied to the company’s share performance.
HeartBeam, Inc. director Richard Ferrari reported an equity award of 50,000 shares of common stock in the form of restricted stock units. The grant was made on February 9, 2026 and increased his directly held position to 229,136 shares.
According to the award terms, one half of the RSU shares will vest on March 31, 2026, and the remaining half will vest on June 30, 2026, based on a vesting commencement date of January 1, 2026. The RSUs were issued under HeartBeam’s 2022 Equity Incentive Plan and carry no cash exercise price.
HeartBeam, Inc. reported that major shareholder Mark E. Strome received a grant of stock options to acquire 41,380 shares of common stock at an exercise price of $1.43 per share. Half of these options vest on March 31, 2026 and the remaining half on June 30, 2026, with an expiration date of January 1, 2036. The options were issued under HeartBeam’s 2022 Equity Incentive Plan and represent compensation rather than an open-market purchase or sale.
HeartBeam, Inc. director receives equity award. Director Michael R. Jaff acquired 20,689 shares of HeartBeam common stock as a grant of restricted stock units (RSUs) at no cash cost on February 9, 2026. Following this award, he holds 95,809 shares directly.
The RSUs were granted under the company’s 2022 Equity Incentive Plan. One half of the shares subject to this special RSU grant are scheduled to vest on March 31, 2026, with the remaining half scheduled to vest on June 30, 2026, subject to the stated vesting terms.
HeartBeam, Inc. reported that President and director Branislav Vajdic received a grant of options to buy 61,932 shares of common stock at an exercise price of $1.45 per share. The options were granted on February 9, 2026 and expire on January 1, 2036.
According to the vesting terms, one half of the shares subject to this special option will vest on March 31, 2026, with the remaining shares vesting on June 30, 2026, based on a vesting commencement date of January 1, 2026. After this grant, Vajdic holds options for 61,932 underlying shares under the company’s 2022 Equity Incentive Plan.
HeartBeam, Inc. reported a routine equity compensation grant to its CFO, Tim Cruickshank. He received stock options covering 53,104 shares of common stock at an exercise price of $1.45 per share. Half of these options vest on March 31, 2026 and the remainder on June 30, 2026 under the 2022 Equity Incentive Plan.
HeartBeam, Inc. director Willem Elfrink received a stock option grant covering 51,724 shares of common stock on February 9, 2026. The options have an exercise price of $1.43 per share and expire on January 1, 2036.
According to the vesting terms, half of the shares subject to this “Special Option” vest on March 31, 2026, with the remaining half vesting on June 30, 2026, based on a vesting commencement date of January 1, 2026. The options were issued under HeartBeam’s 2022 Equity Incentive Plan and represent Elfrink’s reported derivative holdings following this award.
Nelson Kenneth Warwick III reported acquisition or exercise transactions in this Form 4 filing.
HeartBeam, Inc. director Nelson Kenneth Warwick III reported a compensation grant of 17,241 restricted stock units (RSUs) of common stock. These RSUs were granted on February 9, 2026 at no cash cost and increase his direct holdings to 144,388 shares.
According to the grant terms, one half of the RSUs will vest on March 31, 2026, and the remaining half will vest on June 30, 2026, based on a vesting commencement date of January 1, 2026. The award was issued under HeartBeam’s 2022 Equity Incentive Plan, highlighting routine equity-based director compensation rather than an open-market purchase.
HeartBeam, Inc. director George de Urioste received a grant of options to acquire 51,724 shares of common stock at an exercise price of $1.43 per share. Following this award, he holds options covering 51,724 shares.
According to the grant terms, one half of the shares subject to this "Special Option" vest on March 31, 2026, with the remaining half vesting on June 30, 2026, based on a vesting commencement date of January 1, 2026. The options expire on January 1, 2036 and were issued under HeartBeam’s 2022 Equity Incentive Plan.
HeartBeam, Inc. reported that President Robert Paul Eno received an option grant covering 55,172 shares of common stock at an exercise price of $1.45 per share. The award, granted on February 9, 2026, vests half on March 31, 2026 and the remainder on June 30, 2026, and expires on January 1, 2036. These options were issued under the company’s 2022 Equity Incentive Plan and represent equity-based compensation rather than an open-market stock purchase.